Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024  
Regulatory Filings Classification · 95% confidence The document is a press release from Ultimovacs ASA announcing an update to the timeline for reporting topline results from their Phase II INITIUM clinical trial, now expected in March 2024. It details the trial status, endpoints, and context regarding other ongoing trials. This type of announcement, which updates investors on the timing of future data releases or key operational milestones, is typically classified as a general regulatory announcement or investor relations update. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a formal proxy/governance document, and it serves as a general market communication, the most appropriate category is Regulatory Filings (RNS) as a catch-all for important, non-standard announcements, or potentially a Report Publication Announcement (RPA) if it were announcing the *release* of a report, but here it is announcing the *timing* of the results. Given the nature of updating timelines for clinical trial readouts, RNS is the best fit among the provided options for a general, time-sensitive corporate update that isn't a standard financial filing or specific management/governance disclosure.
2024-01-16 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 99% confidence The document text is a template titled 'KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them'. It details a specific transaction (Acquisition of 500 shares for NOK 130 each) by an individual identified as the CEO (Carlos Freitas De Sous) of ULTIMOVACS ASA. This structure and content directly correspond to regulatory filings reporting insider transactions by management personnel. This matches the definition for Director's Dealing (DIRS).
2024-01-04 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document text explicitly states it is a "Mandatory notification of trade by primary insider" concerning the CEO, Carlos de Sousa, buying shares. This directly corresponds to the definition of Director's Dealing (insider trades) provided in the classification list. The relevant code is DIRS.
2024-01-04 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document is explicitly titled 'KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them'. This template is used for reporting insider transactions (trades by directors/executives) to the financial regulator (FINANSTILSYNET OF NORWAY). This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-01-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document text is explicitly titled 'KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them'. It details a transaction (Acquisition) involving a CEO (CARLOS FREITAS DE SOUSA) of ULTIMOVACS ASA, including share volume, price, and date. This content directly corresponds to the reporting requirements for insider trading or director's dealings, which maps precisely to the 'Director's Dealing' category (DIRS).
2024-01-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a "Mandatory notification of trade by primary insider" concerning the CEO, Carlos de Sousa, buying shares. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The filing type code for this is DIRS.
2024-01-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.